Compare IFS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFS | XENE |
|---|---|---|
| Founded | 1897 | 1996 |
| Country | Peru | Canada |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | 2014 | 2014 |
| Metric | IFS | XENE |
|---|---|---|
| Price | $57.74 | $53.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $48.00 | ★ $68.55 |
| AVG Volume (30 Days) | 373.1K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.38 | $2,496.48 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.39 | $30.00 |
| 52 Week High | $57.10 | $62.91 |
| Indicator | IFS | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 70.08 | 50.73 |
| Support Level | $43.65 | $52.90 |
| Resistance Level | N/A | $59.43 |
| Average True Range (ATR) | 1.96 | 1.62 |
| MACD | 0.76 | 0.10 |
| Stochastic Oscillator | 99.36 | 59.89 |
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services, and payments for retail customers and commercial clients in Peru. Its purpose is centered around building financial well-being together. The company has three operating business segments: Banking, mainly loans, credit facilities, deposits, and current accounts; Insurance provides life annuity products with single-premium payment and conventional life insurance products, as well as other retail insurance products; and Wealth management provides brokerage and investment management services. Inteligo serves mainly Peruvian citizens.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.